ABC Content Board

The abc of trending content

Hope of a New Future for Patients with Heart Failure Using New Implantable Hemodynamic Monitoring Technologies, is Highlighted in New Issue of the Journal of the American College of Cardiology

TEL AVIV, Israel–()–A review appearing in the July 18 issue of the Journal of the
American College of Cardiology
(JACC) discusses current and
next-generation implantable hemodynamic monitors and how new approaches
focused on the direct measurement of left atrial pressure (LAP), seek to
expand the use of pressure-guided congestive heart failure (CHF)

The report highlights Vectorious Medical Technologies, an Israeli
company developing the world’s first digital wireless sensory implant
for measuring LAP (currently available CardioMEMS technology is analog
and measures pressure in the pulmonary artery or PAP). Patients with CHF
suffer from repeated admissions to the hospital due to fluid overload,
typically presenting with edema of the legs and congestion of the lungs.
The conventional approach of monitoring symptoms and measuring daily
weights, and a “wait and see” attitude, is the basis for the huge unmet
need of recurrent hospital admissions, because these methods appear late
and are unreliable signs of disease progression. This is also the main
driver of the huge cost of this chronic medical condition, more than $30
billion a year, in the United States alone, according to background
contained in the review.

Intracardiac and PAP-guided management has become a focus of
hospitalization reduction in CHF,” write Drs. William T. Abraham and
Leor Perl. Dr. Abraham is from the Departments of Medicine, Physiology,
and Cell Biology, Division of Cardiovascular Medicine, and the Davis
Heart & Lung Research Institute, The Ohio State University, Columbus,
Ohio. LAP, rather than PAP, is a direct reflection of left ventricular
filling pressure—which is the primary pressure target for CHF
management. Therefore, its direct measurement may…

Read the full article from the Source…

Back to Top